Skip to main content

Advertisement

SpringerLink
Log in

Should patients with malignancy receive chemoprophylaxis against Pneumocystis jirovecii pneumonia?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barbounis V et al. (2005) Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res 25: 651–655

    PubMed  Google Scholar 

  2. Yale SH and Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71: 102–103

    Article  Google Scholar 

  3. Hughes WT et al. (1987) Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316: 1627–1632

    Article  CAS  PubMed  Google Scholar 

  4. Walzer P (2000) Pneumocystis carinii. In Principles and Practice of Infectious Diseases, edn 5, 2789 (Eds Mandell et al.) New York: Churchill Livingstone

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Deputy Director of the Department of Medical Oncology at the St Savas Cancer Hospital, Athens, Greece

    Vassilios Barbounis

Authors
  1. Vassilios Barbounis
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barbounis, V. Should patients with malignancy receive chemoprophylaxis against Pneumocystis jirovecii pneumonia?. Nat Rev Clin Oncol 2, 490–491 (2005). https://doi.org/10.1038/ncponc0299

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0299

  • Springer Nature Limited

Search

Navigation